This document has been accepted by the **Academy Standards Board (ASB)** for development as an American National Standard (ANS). For information about ASB and their process please refer to asb.aafs.org. This document is being made available at this stage of the process so that the forensic science community and interested stakeholders can be more fully aware of the efforts and work products of the Organization of Scientific Area Committees for Forensic Science (OSAC). The documents were prepared with input from OSAC Legal Resource Committee, Quality Infrastructure Committee, and Human Factors Committees, as well as the relevant Scientific Area Committee. The content of the documents listed below is subject to change during the standards development process within ASB and may not represent the contents of the final published standard. All stakeholder groups or individuals are strongly encouraged to submit technical comments on this draft document during the ASB's open comment period. Technical comments will not be accepted if submitted to the OSAC Scientific Area Committees.

Standard for the Analytical Scope and Sensitivity of Forensic Toxicology Urine Testing in Drug-Facilitated Crime Investigations



Draft Document

Standard for the Analytical Scope and Sensitivity of Forensic Toxicology Urine Testing in Drug-Facilitated Crime Investigations

Foreword

Drug-facilitated crimes (DFC) are a public health and safety concern and specialized toxicological testing is a critical part of these investigations. Urine is typically the specimen of choice as it may extend the window of drug detection up to 120 hours (5 days) after the alleged incident. This document is intended to promote standardization of the analytical scope and sensitivity of toxicological testing performed in DFC cases. This document is adapted from the Society of Forensic Toxicologists (SOFT) document entitled *Recommended Minimum Performance Limits for Common DFC Drugs and Metabolites in Urine Samples*. These requirements were developed based on the current prevalence and availability of drugs in the United States. For example, despite popular belief of its use in these crimes, flunitrazepam (Rohypnol) was excluded because the current data do not support its use in DFC in the United States.

All hyperlinks and web addresses shown in this document are current as of the publication date of this standard.

Table of Contents

1	Scope	3
2	Normative References	3
3	Terms and Definitions	3
4	Requirements for Forensic Toxicological Testing of Urine Specimens in Investigations of Drug- Facilitated Crime	4
Tab	le 1	5
Ann	ex A	6

Standard for the Analytical Scope and Sensitivity of Forensic Toxicology Urine Testing in Drug-Facilitated Crime Investigations

1 Scope

This document delineates the minimum requirements for target analytes and analytical sensitivity for the toxicological testing of urine specimens collected from alleged victims of drug-facilitated crimes (DFC). This document does not cover the analysis of blood and other evidence that may be collected in DFC cases.

2 Normative References

Society of Forensic Toxicologists, Recommended Minimum Performance Limits for Common DFC Drugs and Metabolites in Urine Samples. It is available at: <u>http://www.SOFT-Tox.org/files/MinPerfLimits_DFC2017.pdf</u>

3 Terms and Definitions

For purposes of this document, the following definitions and acronyms apply.

3.1

analytical scope

Selection of drugs and drug metabolites covered in an analytical testing scheme.

3.2

analytical sensitivity

The lowest amount of an analyte that can be reliably measured in a specimen by a laboratory test; may be a decision point, a limit of detection or a limit of quantitation.

3.3

decision point

An administratively defined cutoff or concentration that is at or above the method's limit of detection or limit of quantitation and is used to discriminate between positive and negative results.

3.4 drug facilitated crime(s)

DFC

When an individual is victimized while mentally or physically incapacitated due to the effects of ethanol and/or other drugs.

3.5

lower limit of detection

An estimate of the lowest concentration of an analyte in a sample that can be reliably differentiated from blank matrix and identified by the analytical method.

3.6

lower limit of quantitation

An estimate of the lowest concentration of an analyte in a sample that can be reliably measured with acceptable bias and precision.

4 Requirements for Forensic Toxicological Testing of Urine Specimens in Investigations of Drug-Facilitated Crime

4.1 A urine specimen collected from an alleged victim of DFC within 120 hours (5 days) of the incident shall be tested. Case-specific circumstances may warrant testing of specimens collected past 5 days.

4.2 Toxicological testing of urine specimens collected from alleged victims of DFCs shall include, at a minimum, the compounds listed in Table 1. Analytical sensitivity shall meet or exceed (be lower than) the concentrations listed in Table 1. The table reflects total concentrations, which may be achieved via hydrolysis or direct analysis of conjugated compounds.

4.3 Laboratories shall meet the required analytical scope and sensitivity by testing internally, externally, or a combination of both.

4.4 Laboratories shall have a written strategy for addressing case specific circumstances that may not be addressed by the minimum requirements, including:

- when additional specimens (e.g., blood, hair, or biological stains) are received.
- techniques to improve detection (e.g., increasing sample extraction volume).
- utilization of a reference laboratory for the testing of analytes.

4.5 Laboratories shall consider other potentially impairing substances based on factors such as drug-use demographics, regional drug trends, and case histories.

Table 1: Required Minimum Analytical Scope and Sensitivity for Urine Testing in Investigation ofDrug Facilitated Crime

Analyte	Concentration ¹
High-Dose Sedative	S
Ethanol (alcohol) ²	0.01 g/dL
Gamma hydroxybutyrate (GHB) ³	10 μg/mL
Antidepressants	
Amitriptyline	10 ng/mL
Nortriptyline	10 ng/mL
Imipramine	10 ng/mL
Desipramine	10 ng/mL
Trazodone	10 ng/mL
Antihistamines	
Brompheniramine	10 ng/mL
Chlorpheniramine	10 ng/mL
Diphenhydramine	10 ng/mL
Doxylamine	10 ng/mL
Norchlorcyclizine	10 ng/mL
Barbiturates	
Butalbital	100 ng/mL
Phenobarbital	100 ng/mL
Benzodiazepines	
α-hydroxyalprazolam	5 ng/mL
7-aminoclonazepam	5 ng/mL
Lorazepam	5 ng/mL
Nordiazepam	10 ng/mL
Oxazepam	10 ng/mL
Temazepam	10 ng/mL
	40 / 1
Carboxy-tetrahydrocannabinol (THC-COOH)	10 ng/mL
UNS Stimulants	25
Methylenedioxyamphetamine (MDA)	25 ng/mL
Methyleneuloxymethamphetamine (MDMA)	23 lig/lilL
Amphetamine	50 ng/mL
Renzouleggenine	50 lig/lilL
Delizoylecgolille	50 lig/lilL
84144401148440114	
Cyclobonzaprino	10 ng/mI
Cyclobenzaprine Devtromethorphan4	10 ng/mL
Cyclobenzaprine Dextromethorphan ⁴	10 ng/mL 10 ng/mL 10 ng/mL
Cyclobenzaprine Dextromethorphan ⁴ Norketamine	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL
Cyclobenzaprine Dextromethorphan ⁴ Norketamine Zolpidem carboxylic acid	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL
Cyclobenzaprine Dextromethorphan ⁴ Norketamine Zolpidem carboxylic acid Zopiclone	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 100 ng/mL
Miscellaneous Cyclobenzaprine Dextromethorphan ⁴ Norketamine Zolpidem carboxylic acid Zopiclone Carisoprodol Menrohamate	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 100 ng/mL 100 ng/mL
Miscellaneous Cyclobenzaprine Dextromethorphan ⁴ Norketamine Zolpidem carboxylic acid Zopiclone Carisoprodol Meprobamate	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 100 ng/mL 100 ng/mL
Miscellaneous Cyclobenzaprine Dextromethorphan ⁴ Norketamine Zolpidem carboxylic acid Zopiclone Carisoprodol Meprobamate Opioids	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL
Miscellaneous Cyclobenzaprine Dextromethorphan ⁴ Norketamine Zolpidem carboxylic acid Zopiclone Carisoprodol Meprobamate Opioids Fentanyl Norfentanyl	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 100 ng/mL 100 ng/mL 1 ng/mL 1 ng/mL 1 ng/mL
Miscellaneous Cyclobenzaprine Dextromethorphan ⁴ Norketamine Zolpidem carboxylic acid Zopiclone Carisoprodol Meprobamate Opioids Fentanyl Norfentanyl Codeine	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 1 ng/mL 1 ng/mL 1 ng/mL 10 ng/mL
Miscellaneous Cyclobenzaprine Dextromethorphan ⁴ Norketamine Zolpidem carboxylic acid Zopiclone Carisoprodol Meprobamate Opioids Fentanyl Norfentanyl Codeine Morphine	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 1 ng/mL 1 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL
Miscellaneous Cyclobenzaprine Dextromethorphan ⁴ Norketamine Zolpidem carboxylic acid Zopiclone Carisoprodol Meprobamate Opioids Fentanyl Codeine Morphine Hydromorphone	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 1 ng/mL 1 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL
Miscellaneous Cyclobenzaprine Dextromethorphan ⁴ Norketamine Zolpidem carboxylic acid Zopiclone Carisoprodol Meprobamate Opioids Fentanyl Codeine Morphine Hydromorphone Hydrocodone	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 100 ng/mL 10 ng/mL
Miscellaneous Cyclobenzaprine Dextromethorphan ⁴ Norketamine Zolpidem carboxylic acid Zopiclone Carisoprodol Meprobamate Opioids Fentanyl Codeine Morphine Hydromorphone Hydrocodone Oxymorphone	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 10 ng/mL
Cyclobenzaprine Dextromethorphan ⁴ Norketamine Zolpidem carboxylic acid Zopiclone Carisoprodol Meprobamate Opioids Fentanyl Codeine Morphine Hydromorphone Hydrocodone Oxymorphone Oxycodone	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 10 ng/mL

¹All are total drug concentrations; ng/mL is equivalent to μ g/L

²If more than 24 hours has passed between the alleged incident and urine collection testing is not required ³If more than 12 hours has passed between the alleged incident and urine collection testing is not required ⁴Differentiation between d and l isomers is not required

Annex A

(Informative)

Bibliography

1) Anderson, L.J.. Flynn, A. and Pilgrim, J.L. "A Global Epidemiological Perspective on the Toxicology of Drug-Facilitated Sexual Assault: A Systematic Review." J Forensic Leg Med, 2017, pp. 46-54.

2) LeBeau, M.A. "Laboratory Management of Drug-Facilitated Sexual Assault Cases." Forensic Science Review, 2010, pp. 114-119.

3) LeBeau, M.A. and Montgomery, M.A. "Challenges of Drug-Facilitated Sexual Assault." Forensic Science Review, 2010, pp. 2-6.

4) SOFT Society of Forensic Toxicologists *Fact Sheet Drug-Facilitated Sexual Assaults* <u>http://www.soft-tox.org/files/DFSA_Fact_Sheet.pdf</u>, accessed July 9, 2018.

5) UNODC United Nations Office on Drugs and Crime *Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts* December 2011 https://www.unodc.org/documents/scientific/forensic_analys_of_drugs_facilitating_sexual_assault_and_other_criminal_acts.pdf